insitro has announced the acquisition of CombinAbleAI and launched its new TherML platform, a modality-agnostic, AI-powered system that integrates small molecules, oligonucleotides, and biologics into a unified therapeutic design stack. The move signals a strategic attempt to industrialize AI-native drug discovery across modalities while reducing late-stage attrition risks. What makes this acquisition different from typical […]
Find out how Actuate Therapeutics’ elraglusib Phase 2 data at ASCO GI 2026 could change first-line treatment strategies for metastatic pancreatic cancer.
ZYUS Life Sciences launches a C$15–16 million LIFE offering to advance cannabinoid drug development and regulatory execution. Find out what it signals.
Pierre Fabre joins forces with Iktos to discover AI-designed oncology drugs. Find out what this means for cancer R&D, regulatory strategy, and pipeline speed.
